NCT07370532

Etoricoxib in Patients With Parkinsonian Disease

Clinical Study to Evaluate Safety and Efficacy of Etoricoxib in Patients With Parkinson's Disease Treated With Conventional Treatment

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Ihab Elsayed Hassan · Academic / Other
• Sex: All
• Age: 50 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Neuroinflammation is considered one of the most important factors contributing critically to pathophysiology of PD . Recently, high mobility group box-1 (HMGB1) protein has been encoded as a potential inflammatory biomarker in PD. HMGB1 mediates immune response mostly through endothelial cells and macrophage activation via targeting two vital cell receptors; Toll-like receptor 4 (TLR4) and advanced glycation end products (RAGE).

Conditions

• Parkinson Disease

Interventions

Type	Name	Description
DRUG	L-dopa	Levodopa is the standard therapy in PD.
DRUG	Etoricoxib	Etoricoxib, is a selective cyclooxygenase-2 inhibitor. Prostaglandins (PG) are produced from arachidonic acid by the constitutively expressed cyclooxygenase-1(COX-1) and by the inducible COX-2 enzymes and are secreted mainly by astrocytes and microglia.

Timeline

• Start date: 2026-01-30
• Primary completion: 2027-11-10
• Completion: 2027-11-20
• First posted: 2026-01-27
• Last updated: 2026-04-08

Locations

1 site across 1 country: Egypt